| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventricular Dysfunction, Left | 21 | 2022 | 360 | 4.680 |
Why?
|
| Echocardiography | 46 | 2024 | 1049 | 4.440 |
Why?
|
| Ventricular Function, Left | 22 | 2023 | 497 | 3.270 |
Why?
|
| Heart Ventricles | 20 | 2023 | 762 | 2.460 |
Why?
|
| Echocardiography, Doppler | 16 | 2020 | 171 | 2.450 |
Why?
|
| Stroke Volume | 18 | 2023 | 445 | 1.510 |
Why?
|
| Myocardial Contraction | 8 | 2019 | 260 | 1.390 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 9 | 2023 | 43 | 1.360 |
Why?
|
| Anthracyclines | 3 | 2020 | 35 | 1.260 |
Why?
|
| Heart Diseases | 7 | 2023 | 482 | 1.210 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2020 | 126 | 1.130 |
Why?
|
| Hypoplastic Left Heart Syndrome | 5 | 2022 | 252 | 1.120 |
Why?
|
| Ventricular Function | 5 | 2016 | 92 | 1.100 |
Why?
|
| Heart Defects, Congenital | 15 | 2024 | 1804 | 1.060 |
Why?
|
| Child | 72 | 2024 | 24240 | 0.940 |
Why?
|
| Heart Septal Defects, Atrial | 11 | 2023 | 121 | 0.900 |
Why?
|
| Atrial Function, Left | 2 | 2020 | 27 | 0.880 |
Why?
|
| Heart Atria | 5 | 2020 | 313 | 0.860 |
Why?
|
| Predictive Value of Tests | 13 | 2023 | 2111 | 0.830 |
Why?
|
| Neoplasms | 7 | 2023 | 2758 | 0.800 |
Why?
|
| Heart | 8 | 2023 | 723 | 0.770 |
Why?
|
| Cardiac Catheterization | 12 | 2023 | 631 | 0.750 |
Why?
|
| Aortic Valve Stenosis | 5 | 2020 | 332 | 0.710 |
Why?
|
| Anemia, Sickle Cell | 3 | 2020 | 334 | 0.710 |
Why?
|
| Cancer Survivors | 2 | 2020 | 199 | 0.700 |
Why?
|
| Cardiomyopathy, Dilated | 7 | 2016 | 214 | 0.680 |
Why?
|
| Echocardiography, Three-Dimensional | 3 | 2024 | 52 | 0.640 |
Why?
|
| Coronary Aneurysm | 1 | 2019 | 34 | 0.630 |
Why?
|
| Humans | 107 | 2024 | 123133 | 0.610 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 73 | 0.600 |
Why?
|
| Adolescent | 47 | 2024 | 19104 | 0.590 |
Why?
|
| Septal Occluder Device | 5 | 2023 | 42 | 0.590 |
Why?
|
| Child, Preschool | 46 | 2024 | 13900 | 0.550 |
Why?
|
| Infant | 37 | 2024 | 12365 | 0.550 |
Why?
|
| Torsion Abnormality | 1 | 2016 | 34 | 0.540 |
Why?
|
| Pulmonary Valve | 2 | 2017 | 94 | 0.540 |
Why?
|
| Female | 70 | 2024 | 65560 | 0.540 |
Why?
|
| Prospective Studies | 16 | 2022 | 6030 | 0.530 |
Why?
|
| Cardiomyopathies | 5 | 2023 | 478 | 0.510 |
Why?
|
| Cardiology | 1 | 2020 | 473 | 0.490 |
Why?
|
| Male | 63 | 2024 | 60117 | 0.490 |
Why?
|
| Heart Transplantation | 4 | 2020 | 854 | 0.480 |
Why?
|
| Reproducibility of Results | 14 | 2022 | 2828 | 0.470 |
Why?
|
| Ventricular Function, Right | 5 | 2022 | 112 | 0.460 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2024 | 149 | 0.450 |
Why?
|
| Cardiomyopathy, Hypertrophic | 4 | 2009 | 151 | 0.450 |
Why?
|
| Ebstein Anomaly | 1 | 2014 | 26 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2055 | 0.440 |
Why?
|
| Body Surface Area | 4 | 2021 | 31 | 0.430 |
Why?
|
| Systole | 8 | 2022 | 196 | 0.410 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 1661 | 0.400 |
Why?
|
| Electroencephalography | 1 | 2016 | 860 | 0.390 |
Why?
|
| Pheochromocytoma | 1 | 2012 | 33 | 0.390 |
Why?
|
| Adrenalectomy | 1 | 2012 | 35 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 3545 | 0.390 |
Why?
|
| Latin America | 2 | 2022 | 88 | 0.380 |
Why?
|
| Infant, Newborn | 22 | 2023 | 8111 | 0.380 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2012 | 63 | 0.370 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2012 | 107 | 0.350 |
Why?
|
| Infant, Low Birth Weight | 1 | 2010 | 163 | 0.330 |
Why?
|
| Echocardiography, Transesophageal | 6 | 2024 | 238 | 0.330 |
Why?
|
| Blood Flow Velocity | 4 | 2005 | 450 | 0.320 |
Why?
|
| Treatment Outcome | 19 | 2023 | 12129 | 0.310 |
Why?
|
| Observer Variation | 5 | 2021 | 295 | 0.310 |
Why?
|
| Ultrasonography, Interventional | 1 | 2010 | 196 | 0.310 |
Why?
|
| Ultrasonography, Prenatal | 4 | 2020 | 907 | 0.310 |
Why?
|
| Age Factors | 6 | 2021 | 2804 | 0.300 |
Why?
|
| Hemodynamics | 5 | 2021 | 845 | 0.300 |
Why?
|
| Retrospective Studies | 32 | 2024 | 16050 | 0.300 |
Why?
|
| Marfan Syndrome | 2 | 2024 | 137 | 0.300 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2008 | 106 | 0.300 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 3372 | 0.290 |
Why?
|
| Fetal Heart | 2 | 2020 | 111 | 0.290 |
Why?
|
| Heart Valve Diseases | 2 | 2020 | 166 | 0.290 |
Why?
|
| Adult | 26 | 2023 | 29024 | 0.290 |
Why?
|
| Biomechanical Phenomena | 2 | 2019 | 244 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 459 | 0.280 |
Why?
|
| Mitral Valve | 4 | 2024 | 246 | 0.270 |
Why?
|
| Albumins | 1 | 2005 | 88 | 0.240 |
Why?
|
| Ventricular Remodeling | 1 | 2006 | 174 | 0.240 |
Why?
|
| Aortic Valve | 4 | 2016 | 437 | 0.240 |
Why?
|
| Infant, Premature | 1 | 2010 | 800 | 0.240 |
Why?
|
| Fluorocarbons | 1 | 2005 | 56 | 0.240 |
Why?
|
| Renal Dialysis | 2 | 2021 | 842 | 0.230 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1309 | 0.230 |
Why?
|
| Reference Values | 6 | 2021 | 697 | 0.230 |
Why?
|
| Stents | 1 | 2010 | 877 | 0.220 |
Why?
|
| Heart-Assist Devices | 2 | 2018 | 1026 | 0.220 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2016 | 63 | 0.210 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 5050 | 0.210 |
Why?
|
| Feasibility Studies | 3 | 2024 | 755 | 0.210 |
Why?
|
| Risk Factors | 9 | 2020 | 10017 | 0.210 |
Why?
|
| Heart Rate | 4 | 2021 | 586 | 0.200 |
Why?
|
| Pulmonary Artery | 4 | 2015 | 439 | 0.200 |
Why?
|
| Heart Septal Defects, Ventricular | 4 | 2020 | 133 | 0.200 |
Why?
|
| Contrast Media | 1 | 2005 | 470 | 0.190 |
Why?
|
| Cardiotoxicity | 2 | 2020 | 23 | 0.190 |
Why?
|
| Disease Progression | 2 | 2024 | 2028 | 0.190 |
Why?
|
| Brain Chemistry | 1 | 2021 | 122 | 0.190 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 248 | 0.180 |
Why?
|
| Recovery of Function | 3 | 2012 | 437 | 0.180 |
Why?
|
| Aorta | 3 | 2011 | 542 | 0.180 |
Why?
|
| Dilatation | 1 | 2020 | 68 | 0.180 |
Why?
|
| Coronary Vessel Anomalies | 4 | 2015 | 274 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2021 | 214 | 0.170 |
Why?
|
| Body Height | 1 | 2021 | 210 | 0.170 |
Why?
|
| Time Factors | 9 | 2020 | 6223 | 0.170 |
Why?
|
| Pulmonary Valve Stenosis | 2 | 2017 | 40 | 0.160 |
Why?
|
| Electrocardiography | 7 | 2019 | 957 | 0.160 |
Why?
|
| Pregnancy | 6 | 2020 | 7161 | 0.160 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2020 | 114 | 0.160 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1998 | 274 | 0.160 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2019 | 73 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2020 | 141 | 0.160 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1010 | 0.160 |
Why?
|
| Cardiovascular Abnormalities | 2 | 2011 | 51 | 0.150 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2010 | 114 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2015 | 1099 | 0.150 |
Why?
|
| beta-Galactosidase | 1 | 1998 | 145 | 0.150 |
Why?
|
| Oxygen | 1 | 2021 | 550 | 0.150 |
Why?
|
| Reference Standards | 2 | 2016 | 239 | 0.140 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2017 | 39 | 0.140 |
Why?
|
| Ultrasonography | 6 | 2014 | 940 | 0.140 |
Why?
|
| Torsion, Mechanical | 1 | 2016 | 4 | 0.140 |
Why?
|
| Case-Control Studies | 4 | 2020 | 3239 | 0.140 |
Why?
|
| Mitral Valve Stenosis | 2 | 2016 | 34 | 0.140 |
Why?
|
| Linear Models | 2 | 2016 | 669 | 0.140 |
Why?
|
| Time | 1 | 2016 | 94 | 0.140 |
Why?
|
| Prognosis | 7 | 2014 | 4513 | 0.140 |
Why?
|
| Allografts | 1 | 2017 | 190 | 0.130 |
Why?
|
| Shock, Cardiogenic | 1 | 2018 | 187 | 0.130 |
Why?
|
| Saccharomyces cerevisiae | 2 | 1998 | 424 | 0.130 |
Why?
|
| Ventricular Outflow Obstruction | 3 | 2005 | 85 | 0.130 |
Why?
|
| Registries | 1 | 2022 | 1395 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 412 | 0.130 |
Why?
|
| NADP Transhydrogenase, AB-Specific | 1 | 2015 | 4 | 0.130 |
Why?
|
| Gestational Age | 4 | 2016 | 1139 | 0.130 |
Why?
|
| Critical Care | 1 | 2021 | 648 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 764 | 0.120 |
Why?
|
| Heart Conduction System | 1 | 2016 | 145 | 0.120 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 175 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2019 | 1390 | 0.120 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2014 | 42 | 0.120 |
Why?
|
| Dilatation, Pathologic | 2 | 2011 | 93 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 864 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 148 | 0.110 |
Why?
|
| Tetralogy of Fallot | 1 | 1995 | 161 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2003 | 2585 | 0.110 |
Why?
|
| Radiography, Interventional | 2 | 2011 | 87 | 0.110 |
Why?
|
| Global Health | 1 | 2017 | 547 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 444 | 0.110 |
Why?
|
| Incidence | 2 | 2017 | 3044 | 0.100 |
Why?
|
| Balloon Valvuloplasty | 1 | 2012 | 25 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2020 | 3017 | 0.100 |
Why?
|
| Coffin-Lowry Syndrome | 1 | 2011 | 3 | 0.100 |
Why?
|
| Survival Rate | 4 | 2018 | 2000 | 0.100 |
Why?
|
| Prostheses and Implants | 2 | 2005 | 150 | 0.100 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2011 | 21 | 0.100 |
Why?
|
| Texas | 6 | 2016 | 3563 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 434 | 0.090 |
Why?
|
| GATA4 Transcription Factor | 1 | 2011 | 41 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 2850 | 0.090 |
Why?
|
| Femoral Vein | 1 | 2011 | 50 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2011 | 78 | 0.090 |
Why?
|
| Myocardium | 3 | 2023 | 986 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2024 | 4706 | 0.090 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2006 | 145 | 0.090 |
Why?
|
| Brazil | 2 | 2021 | 120 | 0.090 |
Why?
|
| Vena Cava, Inferior | 1 | 2011 | 100 | 0.090 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2011 | 105 | 0.090 |
Why?
|
| Aortic Diseases | 1 | 2013 | 197 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 2014 | 0.090 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 219 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2023 | 270 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 116 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2009 | 22 | 0.080 |
Why?
|
| Cardiotonic Agents | 2 | 2004 | 135 | 0.080 |
Why?
|
| HIV | 1 | 2011 | 179 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2021 | 1172 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 134 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 565 | 0.080 |
Why?
|
| Noonan Syndrome | 1 | 2009 | 29 | 0.080 |
Why?
|
| Maternal Exposure | 1 | 2011 | 147 | 0.080 |
Why?
|
| Heterozygote | 1 | 2011 | 678 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 1004 | 0.080 |
Why?
|
| Mitochondrial Diseases | 1 | 2011 | 135 | 0.080 |
Why?
|
| Exercise Test | 2 | 2007 | 249 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 398 | 0.080 |
Why?
|
| Middle Aged | 9 | 2022 | 26012 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1862 | 0.080 |
Why?
|
| Abnormalities, Multiple | 2 | 2011 | 962 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 1093 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2011 | 638 | 0.080 |
Why?
|
| Infant Welfare | 2 | 2004 | 27 | 0.070 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2020 | 50 | 0.070 |
Why?
|
| Statistics as Topic | 2 | 2004 | 250 | 0.070 |
Why?
|
| Myofibrils | 1 | 2006 | 27 | 0.070 |
Why?
|
| Heart Failure | 2 | 2018 | 2128 | 0.070 |
Why?
|
| Microspheres | 1 | 2005 | 70 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2005 | 50 | 0.060 |
Why?
|
| Pericardial Effusion | 1 | 2005 | 64 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 252 | 0.060 |
Why?
|
| Trisomy | 1 | 2005 | 103 | 0.060 |
Why?
|
| Pediatrics | 2 | 2021 | 1141 | 0.060 |
Why?
|
| Family | 2 | 2005 | 569 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3076 | 0.060 |
Why?
|
| Mitral Valve Prolapse | 1 | 2024 | 28 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2004 | 70 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2007 | 293 | 0.060 |
Why?
|
| Young Adult | 5 | 2018 | 8839 | 0.060 |
Why?
|
| Diastole | 2 | 2020 | 169 | 0.060 |
Why?
|
| Aortic Coarctation | 3 | 2016 | 105 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 169 | 0.060 |
Why?
|
| Catheterization | 1 | 2005 | 235 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2011 | 805 | 0.060 |
Why?
|
| Transposition of Great Vessels | 2 | 2004 | 131 | 0.060 |
Why?
|
| Vectorcardiography | 1 | 2003 | 3 | 0.060 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 68 | 0.060 |
Why?
|
| Tricuspid Valve | 1 | 2004 | 59 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2003 | 44 | 0.060 |
Why?
|
| Mitochondrial Myopathies | 1 | 2003 | 28 | 0.060 |
Why?
|
| Child Welfare | 1 | 2004 | 66 | 0.050 |
Why?
|
| Myocardial Reperfusion | 1 | 2003 | 73 | 0.050 |
Why?
|
| Sinus of Valsalva | 1 | 2003 | 36 | 0.050 |
Why?
|
| Multimodal Imaging | 1 | 2023 | 111 | 0.050 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2004 | 140 | 0.050 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2024 | 156 | 0.050 |
Why?
|
| Mutation | 3 | 2011 | 5771 | 0.050 |
Why?
|
| Milrinone | 1 | 2022 | 30 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2007 | 513 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2003 | 129 | 0.050 |
Why?
|
| Aortic Rupture | 1 | 2003 | 118 | 0.050 |
Why?
|
| Hypoxia, Brain | 1 | 2021 | 34 | 0.050 |
Why?
|
| Fetal Diseases | 1 | 2005 | 440 | 0.050 |
Why?
|
| Stress, Mechanical | 2 | 2016 | 170 | 0.050 |
Why?
|
| Blood Volume | 1 | 2021 | 80 | 0.050 |
Why?
|
| Facies | 2 | 2011 | 155 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 586 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 304 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 713 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 110 | 0.040 |
Why?
|
| Oximetry | 1 | 2021 | 160 | 0.040 |
Why?
|
| ROC Curve | 2 | 2016 | 559 | 0.040 |
Why?
|
| Family Health | 2 | 2015 | 259 | 0.040 |
Why?
|
| Recurrence | 1 | 2003 | 1419 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1258 | 0.040 |
Why?
|
| Wisconsin | 1 | 2019 | 19 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 135 | 0.040 |
Why?
|
| United States | 4 | 2023 | 10652 | 0.040 |
Why?
|
| Hospitals, Pediatric | 2 | 2015 | 780 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 1305 | 0.040 |
Why?
|
| Periplasm | 1 | 1998 | 8 | 0.040 |
Why?
|
| American Heart Association | 1 | 2020 | 295 | 0.040 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 1998 | 15 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 434 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1999 | 127 | 0.040 |
Why?
|
| Ireland | 1 | 2018 | 28 | 0.040 |
Why?
|
| Reoperation | 2 | 2016 | 819 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 450 | 0.040 |
Why?
|
| Proteins | 1 | 2003 | 1037 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2000 | 233 | 0.040 |
Why?
|
| Fetus | 1 | 2021 | 578 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 209 | 0.040 |
Why?
|
| Intermediate Filament Proteins | 1 | 1997 | 27 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1998 | 68 | 0.040 |
Why?
|
| Glycosylation | 1 | 1998 | 114 | 0.040 |
Why?
|
| Peptide Initiation Factors | 1 | 1997 | 30 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2006 | 796 | 0.040 |
Why?
|
| Nomograms | 1 | 2017 | 37 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 84 | 0.040 |
Why?
|
| Culture Media | 1 | 1998 | 183 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1008 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 1998 | 134 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 131 | 0.040 |
Why?
|
| Equipment Design | 2 | 2012 | 604 | 0.040 |
Why?
|
| North America | 1 | 2017 | 239 | 0.030 |
Why?
|
| Dobutamine | 1 | 1997 | 55 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 1996 | 1081 | 0.030 |
Why?
|
| Georgia | 1 | 2016 | 29 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1996 | 65 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 1999 | 227 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2016 | 38 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2016 | 27 | 0.030 |
Why?
|
| Software | 1 | 2021 | 674 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2011 | 266 | 0.030 |
Why?
|
| Hospitalization | 1 | 2004 | 1728 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 548 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 383 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 1997 | 399 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1997 | 421 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2011 | 237 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 2015 | 87 | 0.030 |
Why?
|
| Fistula | 1 | 1995 | 50 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2015 | 56 | 0.030 |
Why?
|
| Pedigree | 2 | 2015 | 1576 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 157 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2015 | 142 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 1995 | 180 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 1999 | 520 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 3317 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 316 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 577 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 1 | 2014 | 80 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 348 | 0.030 |
Why?
|
| Siblings | 2 | 2005 | 196 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 1262 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 239 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1115 | 0.030 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 13 | 0.030 |
Why?
|
| Atenolol | 1 | 2013 | 43 | 0.030 |
Why?
|
| Losartan | 1 | 2013 | 33 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 1997 | 899 | 0.030 |
Why?
|
| Tachycardia | 1 | 2013 | 68 | 0.030 |
Why?
|
| Atrial Flutter | 1 | 2013 | 32 | 0.030 |
Why?
|
| Shock, Septic | 1 | 1994 | 146 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1496 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 51 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2015 | 295 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1473 | 0.030 |
Why?
|
| Miniaturization | 1 | 2012 | 27 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2015 | 350 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2015 | 420 | 0.030 |
Why?
|
| Zebrafish | 1 | 2015 | 386 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1998 | 983 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1997 | 1017 | 0.030 |
Why?
|
| Angiography | 2 | 2006 | 215 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 235 | 0.020 |
Why?
|
| Ureteral Diseases | 1 | 1991 | 5 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 1991 | 7 | 0.020 |
Why?
|
| HIV Infections | 1 | 2004 | 1855 | 0.020 |
Why?
|
| Dextrocardia | 1 | 2011 | 9 | 0.020 |
Why?
|
| Cineangiography | 2 | 2005 | 15 | 0.020 |
Why?
|
| Scopolamine Derivatives | 1 | 1991 | 11 | 0.020 |
Why?
|
| Dystrophin | 1 | 2011 | 37 | 0.020 |
Why?
|
| Nifedipine | 1 | 1991 | 21 | 0.020 |
Why?
|
| Colic | 1 | 1991 | 9 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2011 | 37 | 0.020 |
Why?
|
| Gene Order | 1 | 2011 | 78 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2014 | 672 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2011 | 119 | 0.020 |
Why?
|
| Heterotaxy Syndrome | 1 | 2011 | 61 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 621 | 0.020 |
Why?
|
| Chromosome Duplication | 1 | 2011 | 147 | 0.020 |
Why?
|
| Exome | 1 | 2015 | 1040 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3667 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 573 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 529 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 2011 | 309 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1751 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 1176 | 0.020 |
Why?
|
| Belgium | 1 | 2008 | 43 | 0.020 |
Why?
|
| Heart Septum | 1 | 2008 | 55 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1798 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2012 | 429 | 0.020 |
Why?
|
| Lod Score | 2 | 1996 | 120 | 0.020 |
Why?
|
| Phenotype | 2 | 2011 | 4226 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1998 | 4493 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 767 | 0.020 |
Why?
|
| Elasticity | 1 | 2005 | 92 | 0.020 |
Why?
|
| Hydrops Fetalis | 1 | 2005 | 75 | 0.020 |
Why?
|
| Fetal Death | 1 | 2005 | 113 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2005 | 106 | 0.010 |
Why?
|
| Genetic Linkage | 2 | 1996 | 452 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 143 | 0.010 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2004 | 21 | 0.010 |
Why?
|
| Aged | 4 | 2005 | 19110 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 294 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2005 | 136 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 409 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2004 | 61 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 2004 | 26 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2004 | 169 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 309 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 235 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 75 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1683 | 0.010 |
Why?
|
| Chest Pain | 1 | 2004 | 124 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 197 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 307 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 614 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 745 | 0.010 |
Why?
|
| Tachycardia, Ventricular | 1 | 2004 | 197 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 1876 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2004 | 341 | 0.010 |
Why?
|
| Prosthesis Implantation | 1 | 2001 | 143 | 0.010 |
Why?
|
| Integrin beta4 | 1 | 1997 | 3 | 0.010 |
Why?
|
| Intermediate Filaments | 1 | 1997 | 7 | 0.010 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 1997 | 35 | 0.010 |
Why?
|
| Solubility | 1 | 1997 | 132 | 0.010 |
Why?
|
| Animals | 2 | 2015 | 33803 | 0.010 |
Why?
|
| Ribosomal Proteins | 1 | 1997 | 73 | 0.010 |
Why?
|
| Parents | 1 | 2004 | 1031 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 473 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1997 | 288 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1997 | 623 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1996 | 73 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 258 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 106 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1995 | 139 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1997 | 674 | 0.010 |
Why?
|
| Biomarkers | 1 | 2004 | 2944 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 6376 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1386 | 0.010 |
Why?
|
| Protein Binding | 1 | 1997 | 1742 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 2696 | 0.010 |
Why?
|
| Gene Expression | 1 | 1997 | 1565 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 1995 | 224 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 3868 | 0.010 |
Why?
|
| Resuscitation | 1 | 1994 | 244 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1997 | 2809 | 0.010 |
Why?
|
| Remission Induction | 1 | 1991 | 300 | 0.010 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 1994 | 470 | 0.010 |
Why?
|
| Emergencies | 1 | 1991 | 174 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1994 | 1325 | 0.000 |
Why?
|
| Mice | 1 | 1997 | 17541 | 0.000 |
Why?
|